Immune intervention in HPV infections: Current progress and future developments - July 10-13 2003, HPV Vaccines and Immunotherapies, Robinson College, Cambridge, UK

Expert Review of Vaccines

Volumn 2, Issue 5, 2003, Pages 615-617

  Stanley, Margaret ^a  

^a Department of Pathology ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMIDAZOQUINOLINE DERIVATIVE; IMIQUIMOD; UNCLASSIFIED DRUG; VIRUS VACCINE; WART VIRUS VACCINE;

CLINICAL TRIAL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNE RESPONSE; INFECTION CONTROL; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN TARGETING; TREATMENT OUTCOME; UTERINE CERVIX CANCER; VACCINATION; VERRUCA VULGARIS; VIRUS PARTICLE; VIRUS STRAIN; WART VIRUS;

FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RANDOMIZED CONTROLLED TRIALS; UTERINE CERVICAL NEOPLASMS; VACCINATION; VIRAL VACCINES;

EID: 0142026124     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.2.5.615     Document Type: Conference Paper

References (1)

1. Koutsky LA, Ault KA, Wheeler Cm et al. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347(21), 1645-1651 (2002).